Drugs and patents in ATC class V08AA - Watersoluble, nephrotropic, high osmolar X-ray contrast media

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
ISOPAQUE 280	calcium; meglumine; metrizoic acid
RENOVUE-65	iodamide meglumine
RENOVUE-DIP	iodamide meglumine
>Tradename	>Generic Name

Last updated: June 12, 2026

Executive summary

ATC V08AA high osmolar, water-soluble, nephrotropic iodinated X-ray contrast media remain a global niche relative to modern low-/iso-osmolar nonionic products, but they still support recurring volumes in older imaging workflows and constrained formularies. The patent estate is dominated by legacy iodinated small-molecule actives and process/formulation improvements rather than broad new-molecule exclusivity. In practice, market entry risk is driven by (1) Orange Book-style branded product remnants in the US where applicable, (2) method-of-manufacture and sterile/handling patents, and (3) regulatory reliance and pharmacovigilance constraints that affect switch timing after safety signals. Competitive pressure is anchored in cost and supply-chain reliability, with generic and “authorized” supply common once primary active and key manufacturing protections expire.

What patents protect ATC V08AA high osmolar X-ray contrast media?

Featured snippet answer: Patents for ATC V08AA products typically cover legacy iodinated active ingredients only where newer salts, concentrations, sterilization/process controls, or specific manufacturing controls remain, plus formulation/sterility and manufacturing methods that can block generic replication even after active ingredient patent expiry.

Which active ingredients define ATC V08AA?

ATC V08AA is defined by therapeutic classification rather than a single molecule. The “high osmolar” and “nephrotropic, water-soluble X-ray contrast media” description maps to older ionic, iodinated contrast agents that are generally produced as aqueous solutions and dosed for intravascular imaging. In most jurisdictions, these older ionic agents entered the market decades earlier, so the primary active ingredient patents largely expired long ago. As a result, today’s patent landscape is most often process- and product-formulation oriented.

Patent categories that still matter commercially

Sterile aqueous manufacturing processes
- Controls for iodine chemistry stability, particulate/filtration strategy, and aseptic fill.
Stability and shelf-life extension
- Storage conditions, packaging interactions, and stabilization strategies that reduce precipitation or degradation.
Container/closure and delivery system
- Elastomer or stopper interactions, needle access systems, and transfer-device constraints tied to sterility assurance.
Concentration-specific formulations
- Different iodine concentrations or volumes may have distinct process controls and labeling, leading to separate IP around how that strength is produced and released.
Use-related claims
- Method-of-use claims can exist around dosing regimens or patient subpopulations, but these are less common as core imaging protocols become standardized.

How to read the estate: what typically survives

For legacy high osmolar ionic agents, surviving IP tends to be:

Narrow, manufacturing-process claims (e.g., specific reaction workups, purification steps, filtration/sterilization parameters).
Narrow formulation and stability claims tied to particular strengths and packaging.
Constrained method-of-use claims that may offer incremental leverage but rarely prevent generic “equivalence” if regulatory requirements and labeling carve-outs are satisfied.

When does ATC V08AA high osmolar contrast media lose exclusivity?

Featured snippet answer: Exclusivity for the active ingredients is generally long expired; remaining exclusivity is usually tied to later formulation/process patents, which expire on a different schedule and can vary by product strength and manufacturer.

Typical exclusivity timeline structure for legacy ionic agents

Active ingredient patents: mostly expired in major markets.
Formulation/process patents: last for roughly 20 years from filing, often ending later than the original compound, creating staggered last-patent-expiry by product strength.
Regulatory exclusivity: may apply to specific NDA/BLA approvals in the US if a product is newer than the legacy compound, but for many high osmolar agents, submissions are older and exclusivity windows are likely already elapsed.

Practical implication for investors and litigators

Even where the “active ingredient” is off-patent, generics can still face:

Process claim barriers if the competitor’s manufacturing method is non-infringing by design or cannot be proven as such.
Formulation/sterility claims that are difficult to avoid if the product must match concentration and sterility performance.
Settlement-driven launch timing if a brand or pioneer blocks entry via litigation leverage rather than strong active ingredient patents.

What generic entry risks exist for high osmolar nephrotropic X-ray contrast media?

Featured snippet answer: Generic entry risk is highest from process/formulation patents and from regulatory and quality system constraints that can trigger non-infringement disputes or delayed approvals, even when active ingredient is off-patent.

Key infringement vectors

Sterilization and filtration sequence: claims that specify sterilization conditions or filtration thresholds can be difficult to design around if the generic must meet identical specs.
Stability and particulate control: generic release testing must demonstrate equivalence; if a patent covers the method of controlling degradation/particulates, dispute risk rises.
Concentration-specific manufacturing: even if the molecule is the same, claims by strength (e.g., mgI/mL ranges) can create “strength-by-strength” non-infringement opportunities.

Regulatory entry vectors

505(b)(2) or ANDA reliance: pathways depend on whether a US reference listed drug exists and whether bridging data is required for the specific strength and presentation.
Labeling equivalence: if a patented method-of-use influences labeling, carve-outs or updated instructions may be negotiated.

How strong is the patent estate for ATC V08AA high osmolar contrast media?

Featured snippet answer: The estate is usually fragmented and weak against full generic replacement because it is often limited to narrow manufacturing or formulation improvements, not broad composition claims.

What “strong” looks like in this class

Patent strength is concentrated in:

Process claims with tight technical steps that are hard to replicate without reading on claims.
Packaging/stability claims tied to a specific container configuration that affects sterility and shelf life.
Method-of-use claims that tie to dosing schedules used in label language, which can drive carve-out negotiations.

What “weak” looks like

Broad composition claims over ionic iodinated contrast media structures are unlikely to remain enforceable.
Stability claims that can be covered by multiple stabilization approaches are harder to enforce across variants.

What is the Orange Book status of ATC V08AA high osmolar contrast media?

Featured snippet answer: Orange Book listings exist at the product level when a listed drug is tied to an NDA with listed patents, but for many legacy high osmolar agents the relevant listed patents have likely aged out; remaining listings are typically formulation/process.

Note: Without a specific drug name or country product identifier, a reliable Orange Book-by-product mapping cannot be produced.

What formulations are protected by patents for high osmolar, water-soluble iodinated contrast media?

Featured snippet answer: Patents most often protect stability-controlled aqueous formulations, sterilized sterile-aqueous processes, and container/closure combinations for specific iodine concentrations and fill volumes.

Dosage form and concentration: why it matters

High osmolar agents are typically supplied as aqueous injection solutions.
The iodine concentration and volume per vial are key discriminators for patent scope in practical disputes because claims are often written to those parameters.

Container/closure is a frequent differentiator

Sterility assurance and adsorption of iodine species can lead to patents over:

vial/stopper combinations,
transfer systems (spike-based access),
and packaging handling parameters tied to shelf-life and particulate profiles.

How does ATC V08AA compare with low-/iso-osmolar iodinated contrast patent estates?

Featured snippet answer: Low-/iso-osmolar nonionic agents have more modern commercial IP histories, including broader product-platform patents, while high osmolar ionic agents generally have older, narrower process/formulation protections.

Market dynamic: substitution pressure

Clinicians and payers increasingly prefer low-/iso-osmolar nonionic agents due to reduced adverse event rates in many settings, which compresses the ceiling for high osmolar volume growth. This drives:

generic cost pressure,
procurement rationalization,
and faster substitution once safety data and logistics allow.

Competitive impact on patent enforcement

When a class faces strong substitution pressure, parties often use litigation leverage to manage:

inventory timing,
tender eligibility,
and transition planning rather than to preserve high margin.

What patent litigation affects high osmolar contrast media products?

Featured snippet answer: Litigation, where it occurs, most often targets generic process and formulation equivalence through Paragraph IV-style or non-ANDA challenges in jurisdictions with compatible legal mechanisms, focusing on manufacturing steps and stability/sterility claims.

Typical litigation playbook in this class

Assert narrow process/formulation patents tied to the specific strength and presentation.
Seek injunctions tied to exclusivity or to infringement of specific manufacturing claims.
Use settlement to time generic entry aligned to production readiness and regulatory approval windows.

Note: Without specific product names or jurisdictional case captions, a complete litigation map cannot be generated.

How do licensing deals shape supply and generic launch timing?

Featured snippet answer: Licensing is most likely to appear in a legacy market where multiple generics compete on procurement bids and a pioneer or brand holder seeks to de-risk manufacturing transfers and quality systems.

Why licensing is rational here

High osmolar sterile injectables require robust aseptic manufacturing and particulate control.
Licensing can secure:
- access to validated processes,
- know-how on stability management,
- and controlled supply for procurement tenders.

Which companies compete in ATC V08AA high osmolar contrast media, and how is market share shifting?

Featured snippet answer: Competition is primarily among generic sterile injectable manufacturers and distributors; shifts come from tendering, supply reliability, and substitution to low-/iso-osmolar agents rather than from rapid innovation in the high osmolar segment.

Commercial drivers that move volumes

Tender pricing and contract terms
Supply continuity and production capacity
Institutional formularies and clinical pathway adoption
Safety and pharmacovigilance signals
Regulatory inspections affecting availability

How substitution changes bargaining power

As payers and hospitals shift usage, high osmolar products become:

more price-elastic,
less tolerant of shortages,
and more exposed to “switch costs” only when low-/iso-osmolar supply is constrained.

Key market dynamics for ATC V08AA high osmolar contrast media

Featured snippet answer: The market is in a structural decline relative to low-/iso-osmolar nonionic agents in many mature healthcare systems, while maintaining steady demand in specific imaging protocols and procurement-constrained settings.

Demand profile by use setting

Hospitals and imaging centers with legacy protocols.
Regions with constrained budgets or limited access to nonionic alternatives.
Periods where supply of alternatives is strained.

Supply chain and manufacturing constraints

Sterile injectable production is capacity constrained by:

aseptic fill lines,
quality system requirements,
and validation capacity for particulate and stability release.

Revenue exposure and margin pressure

Price competition compresses unit margins.
Patented protection, where present, typically supports only incremental premiums around specific strengths/presentations or around continued supply commitments.

What generic launch scenarios exist if key patents expire?

Featured snippet answer: If remaining process/formulation patents expire, generic launches usually occur in a staggered pattern by strength and packaging, with regulatory approval constrained by stability bridging and sterility validation.

Launch sequence mechanics

Start with the most demanded strength and presentation to capture tender share.
Use bioequivalence or bridging strategies where allowable.
Ensure particulate and stability data meet the reference product’s release and shelf-life criteria.

Non-infringement design-around scenarios

Generic entrants can reduce risk by:

altering specific sterilization parameters where allowed,
using alternative filtration strategies that avoid claim elements,
and changing packaging/closure details where claims cover container/closure interactions.

Geographic scope: where patents and exclusivity most affect market access?

Featured snippet answer: Exclusivity and enforcement impact is strongest where local manufacturing and regulatory submission depend on product-level IP listings and where courts reliably enforce narrow process claims.

Practical jurisdiction map

US: Orange Book listings and ANDA litigation risk where patents are listed for a reference listed drug.
Europe: EP national validation and local injunction frameworks; enforcement often focuses on granted claims in key member states.
UK, Canada, Japan: similar small-molecule process/formulation enforcement patterns, with variation in how generic challenges are handled.

Note: Without a named product and jurisdiction, a definitive jurisdiction-by-jurisdiction patent table cannot be produced.

Key takeaways

ATC V08AA high osmolar, water-soluble nephrotropic iodinated contrast media are legacy products in a competitive market pressured by substitution to low-/iso-osmolar nonionic agents.
The enforceable patent estate, where present, is typically narrow and centered on sterile aqueous manufacturing, stability control, container/closure, and sometimes strength-specific formulation or method-of-use claims.
Generic entry risk is driven less by active ingredient patents and more by process/formulation details and sterility/stability equivalence, which can trigger litigation and settlement-based entry timing.
Market dynamics are dominated by procurement pricing, supply reliability, and formulary substitution decisions more than by patent-driven exclusivity.

FAQs

1) What patents are most commonly asserted against generics for high osmolar iodinated contrast media?
Process claims tied to sterilization/filtration steps, stability-controlled manufacturing parameters, and strength-specific formulation claims.

2) Do high osmolar contrast products face Paragraph IV-style challenges in the US?
Where product-level Orange Book listings exist for an applicable US reference listed drug, challenges often target listed formulation/process patents rather than the active ingredient.

3) Can a generic avoid infringement by changing manufacturing parameters for sterile injections?
If claims are specific to certain process parameters, generics can attempt non-infringement design-arounds through different sterilization and filtration sequences, subject to regulatory equivalence.

4) How does container/closure affect patent and regulatory risk for sterile contrast media?
Container/closure and closure-handling can be patented for stability and sterility assurance; regulatory equivalence also depends on maintaining particulate and degradation profiles.

5) What is the fastest commercial path to switch from high osmolar to low-/iso-osmolar agents?
Formulary and tender updates, supported by clinical guideline adoption and procurement contracting, typically drive substitution faster than patent expiry alone.

References

WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index: V08AA. World Health Organization.
U.S. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
EMA. European public assessment reports and product information for iodinated contrast media. European Medicines Agency.